New treatment for people with alopecia

The ALOPECIA study: A clinical trial to assess a new drug for alopecia areata

Alopecia areata is an autoimmune disease characterised by loss if hair in single or multiple areas of the scalp, face or body. The scalp is most commonly affected.

The purpose of this study is to compare the effects of the PF-06651600 with a placebo to find out which is better for treating alopecia areata.  Researchers will compare the results of taking the placebo to the results of taking PF-06651600 to see if there are any differences.

Anticipated date that enrolment will close: TBA

Who can take part

Inclusion Criteria

  • 12 years and over
  • Clinical diagnosis of alopecia areat

Exclusion Criteria

  • History of any progressive/sudden hearing loss.
  • History of current malignancy except adequately treated or excised
    • non metastatic basal cell carcinoma
    • squamous cell carcinoma
    • cervical carcinoma in situ
  • History of lymphoproliferative disorder

What is involved for you

  • 14 visits over 53 weeks
  • blood/urine samples
  • chest x-ray
  • weight
  • blood pressure
  • injections
check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2019.012
Annette Phemister
03 9342 4531